A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients

NCT01631812 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: SPM 962

Sponsor

Otsuka Pharmaceutical Co., Ltd.